´ó·¢ÁùºÏ²Ê

I'm a pharmaceutical company

936X874 Disclosure

What doÌýyou need to know?

All ´ó·¢ÁùºÏ²Ê members and any pharmaceutical company thatÌýfollowsÌýÌýare required to disclose annually transfers of value - certain payments and benefits in kind -Ìýmade to healthcare professionals (HCPs) and healthcare organisations (HCOs).Ìý

Why do pharmaceutical companies need to disclose?

The disclosure of certain transfer of value made toÌýHCPs and HCOsÌýis about bringing further transparency to the relationship between the pharmaceutical industry and thoseÌýit works with.

It is a relationship that is critical to the future of medical innovation and patient care and as such, should meet the high expectations of patient and wider stakeholders.

Disclosing details of certain payments and benefits in kind​​​ made to individual HCPs and HCOs is part of a Europe-wide initiative to increase transparency. It also builds on the ´ó·¢ÁùºÏ²Ê Code of Practice requirements to disclose certain payments which have been made in total since 2012.

Last modified: 01 July 2024

Last reviewed: 01 July 2024